NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA
NCT04284774 2025-12-04Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialNational Cancer Institute (NCI)Phase 2 Active not recruiting5 enrolled 9 charts
NCT06638931 2025-05-28ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Active not recruiting28 enrolled